CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Alnylam Pharmaceuticals Q3 revenue rises on AMVUTTRA demand

By Reuters News


Overview

  • RNAi therapeutics firm's Q3 net product revenue rose 52% yr/yr, driven by AMVUTTRA demand

  • Company expanded TRITON-CM Phase 3 study enrollment for nucresiran


Outlook

  • Alnylam reiterates 2026 total net product revenue guidance of $4.7 bln to $5.1 bln

  • Company expects 2026 TTR net product revenues of $4.2 bln to $4.5 bln

  • Alnylam forecasts 2026 Rare net product revenues of $500 mln to $600 mln


Result Drivers

  • AMVUTTRA DEMAND - Co said Q3 revenue growth was mainly driven by increased patient demand for AMVUTTRA, especially in ATTR-CM in the U.S.

  • INVENTORY AND PRICING - Co said U.S. TTR revenue growth benefited from inventory adjustments and favorable gross-to-net pricing in Q3

  • INTERNATIONAL LAUNCHES - Co said international TTR revenue growth was driven by ATTR-CM launches in Japan, Germany, and Italy


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted EPS

$16.26

Q3 Adjusted Net Income

$2.24 bln

Q3 Net Income

$2.17 bln

Q3 Adjusted Operating income

$424.92 mln

Q3 Operating Income

$345.80 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Alnylam Pharmaceuticals, Inc. is $350.00, about 50.6% above its October 28 closing price of $232.40

  • The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 33 three months ago


Reuters Recommended Reads

  • Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength

  • Oct 29 - Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges

  • Oct 28 - Viking Therapeutics posts bigger-than-expected Q3 loss as costs rise


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.